Tyrosine Kinase
- IGFBR(1)
- Bcr-Abl(73)
- Ack1(4)
- Axl(6)
- ALK(61)
- BMX Kinase(4)
- Broad Spectrum Protein Kinase Inhibitor(11)
- c-FMS(35)
- c-Kit(65)
- c-MET(91)
- c-RET(7)
- CSF-1R(3)
- DDR1/DDR2 Receptor(1)
- EGFR(251)
- EphB4(2)
- FAK(34)
- FGFR(104)
- FLT3(102)
- HER2(19)
- IGF1R(33)
- Insulin Receptor(45)
- IRAK(32)
- ITK(12)
- Lck(2)
- LRRK2(23)
- PDGFR(117)
- PTKs/RTKs(5)
- Pyk2(6)
- ROR(41)
- Spleen Tyrosine Kinase (Syk)(35)
- Src(105)
- Tie-2 (3)
- Trk(37)
- VEGFR(203)
- Kinase(0)
- Discoidin Domain Receptor(15)
- DYRK(26)
- Ephrin Receptor(13)
- ROS(15)
- RET(34)
- TAM Receptor(28)
Products for Tyrosine Kinase
- Cat.No. Product Name Information
- GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1.
-
GC14292
Apatinib Mesylate
Apatinib blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.
- GC49799 Apatinib-d8 An internal standard for the quantification of apatinib
- GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research.
- GC12478 ARRY-380 ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2.
- GC46013 AS-2444697 (hydrochloride) AS-2444697 (hydrochloride) is an orally active IRAK-4 inhibitor with an IC50 of 21 nM.
- GC32703 Asciminib (ABL001) Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
- GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM.
- GC62402 ASK120067 ASK120067 (ASK120067) is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research ofnon-small cell lung cancer (NSCLC).
- GC14446 ASP3026 An ALK inhibitor
- GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity.
- GC10914 AST 487 A multi-kinase inhibitor
- GC11691 AST-1306 AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity.
- GC15669 AST-1306 TsOH AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity
- GC33096 AST2818 mesylate Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC).
- GC62481 AST5902 trimesylate AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor.
- GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing.
- GC10638 AT9283 A broad spectrum kinase inhibitor
- GC62499 ATH686 ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects.
- GC35435 AV-412 A dual inhibitor of EGFR and HER2
- GC35436 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively.
- GC19074 Avapritinib Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V.
-
GC42884
Avitinib
Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR).
-
GC19044
Avitinib maleate
A pyrrolopyrimidine-based irreversible EGFR inhibitor
- GC64683 AVJ16 AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes.
- GC12216 Axitinib (AG 013736) Axitinib (AG 013736) is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
- GC42887 Axitinib Sulfoxide Axitinib sulfoxide is a major inactive metabolite of the tyrosine kinase inhibitor axitinib.
- GC46899 Axitinib-13C-d3 An internal standard for the quantification of axitinib
- GC62185 Axitinib-d3 Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively.
- GC17045 AXL1717 A potent and selective inhibitor of IGF-1R
- GC50221 AZ Dyrk1B 33 Potent and selective Dyrk1B kinase inhibitor
- GC33090 AZ-23 (AZ23) AZ-23 (AZ23) is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively.
- GC64071 AZ14145845 AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy.
- GC33054 AZ1495 An oral active inhibitor of IRAK4
- GC17654 AZ191 DYRK1B inhibitor,potent and selective
- GC12955 AZ5104 EGFR inhibitor
- GC33072 AZ7550 AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
- GC34287 AZ7550 hydrochloride AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM.
- GC34414 AZ7550 Mesylate (AZ7550 trimesylate salt)
- GC31880 AZD-0284 AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ.
- GC14189 AZD-3463 ALK/IGF1R inhibitor
- GC16308 AZD-9291 AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
- GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
- GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit
- GC33027 AZD3229 An inhibitor of c-Kit-driven cell proliferation
- GC33246 AZD3229 Tosylate AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors.
- GC13143 AZD3759 AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively.
- GC14005 AZD4547 FGFR inhibitor
-
GC19404
AZD7507
AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity)
- GC13761 AZD8931 (Sapitinib) AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively.
- GC32875 AZM475271 (M475271) AZM475271 (M475271) is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2.
- GC18580 B355252 A neuroprotective agent
-
GC35462
Bafetinib
Bcr-Abl/Lyn tyrosine kinase inhibitor
-
GC68727
Barzolvolimab
Barzolvolimab (CDX 0159) is a humanized monoclonal antibody against KIT IgG1. Barzolvolimab specifically and effectively inhibits the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria.
- GC64377 Batatasin III Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities.
- GC11726 BAW2881 (NVP-BAW2881) BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM.
- GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG).
- GC16389 BAY 61-3606 A Syk inhibitor
- GC12136 BAY 61-3606 dihydrochloride
- GC19062 BBT594 BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.
- GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia.
- GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively.
- GC12186 BDNF (human) activator of TrkB and p75 neurotrophin receptors
- GC60629 BDTX-189 BDTX-189 (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity.
- GC64017 Befotertinib Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC).
- GC19063 Belizatinib Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase.
- GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research.
- GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab (Anti-Human VEGF, Humanized Antibody), a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity.
- GC63436 Bevurogant Bevurogant is a retinoid-related orphan receptor-gamma t (RORγt) antagonist.
-
GC64810
Bezuclastinib
Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001
- GC15340 BFH772 VEGFR2 inhibitor
- GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively.
- GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively.
- GC10055 BGJ398 An FGFR inhibitor
- GC65457 BI-3663 BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 linked to Pomalidomide with a linker. Anti-cancer activity.
- GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor
- GC34488 BI-4464 BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC.
- GC65886 BI-853520 BI 853520 (IN-10018) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1nM). BI 853520 shows anti-proliferative activity against cancer cells.
- GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM.
- GC10815 BIBU 1361 dihydrochloride EGFR inhibitor
- GC10087 BIBX 1382 An EGFR inhibitor
- GC50026 BIBX 1382 dihydrochloride Highly selective EGFR-kinase inhibitor
- GC19075 BLU-554 BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling.
- GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC).
- GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible
- GC12539 BLZ945 BLZ945 (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs.
- GC14136 BMS 599626 dihydrochloride EGFR and ErbB2 inhibitor,potent and selective
- GC50330 BMS 605541 Potent VEGFR-2 inhibitor
- GC10455 BMS-509744
-
GC17773
BMS-536924
IR/IGF-1R inhibitor
- GC10606 BMS-599626 Hydrochloride
- GC13873 BMS-690514
- GC16712 BMS-754807 IGF-1R/InsR inhibitor,potent and selective
-
GC14214
BMS-777607
BMS-777607 is a pan-TAM inhibitor, which shows anti-tumor activity to different types of cancer.
- GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive
- GC17772 BMS-817378 Potent ATP competitive inhibitor of Met/VEGFR2
- GC11063 BMX-IN-1 A selective BMX and BTK inhibitor
- GC13343 Bosutinib (SKI-606) Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively.
- GC40080 Bosutinib-d8 Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS.
- GC38894 Bozitinib Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily.